Blog
RSS FeedPosted by Michael Wonder on 23 Oct 2020
Strengthening global collaboration on COVID-19 real-world evidence and observational studies
23 October 2020 - Medicines regulators from around the world discussed their experiences with supporting and assessing real-world evidence to facilitate ...
Posted by Michael Wonder on 08 Oct 2020
Use of real world evidence to support FDA approval of oncology drugs
8 October 2020 - Real world evidence has gained increased attention in recent years as a complement to traditional clinical trials. ...
Posted by Michael Wonder on 05 Oct 2020
Real world evidence from a narrow therapeutic index product (levothyroxine) reflects the therapeutic equivalence of generic drug product
5 October 2020 - The National Institute of Diabetes and Digestive and Kidney Diseases reports that almost 5% of the U.S. ...
Posted by Michael Wonder on 22 Sep 2020
Taking steps toward transparency in real world evidence studies
22 September 2020 - The level of trust in health economics and outcomes research studies has been an on-going concern owing ...
Posted by Michael Wonder on 31 Jul 2020
Global regulatory workshop on COVID-19 real-world evidence and observational studies
31 July 2020 - Vaccines surveillance and vigilance, collaboration on pregnancy studies and building international patient cohorts were the main ...
Posted by Michael Wonder on 21 Jul 2020
Harnessing real world data for regulatory use and applying innovative applications
22 July 2020 - A vast quantity of real world data are available to health care researchers. ...
Posted by Michael Wonder on 21 Jul 2020
EMA sets up infrastructure for real-world monitoring of COVID-19 treatments and vaccines
21 July 2020 - EMA has now set up an infrastructure to support the monitoring of the efficacy and safety ...
Posted by Michael Wonder on 27 May 2020
EMA commissions independent research to prepare for real world monitoring of COVID-19 vaccines
27 May 2020 - EMA is engaging early with researchers to ensure that a European infrastructure will be in place to ...
Posted by Michael Wonder on 19 May 2020
(COVID-19) update: FDA collaborations promote rigorous analyses of real world data to inform pandemic response
19 May 2020 - Today, the FDA is announcing another step in our effort to harness diverse streams of data to ...
Posted by Michael Wonder on 16 Apr 2020
Meeting highlights from ICMRA global regulatory workshop on COVID-19 observational studies and real world data
16 April 2020 - Observational studies of data generated in clinical practice in the context of COVID-19 can contribute to the ...
Posted by Michael Wonder on 07 Apr 2020
Global regulators discuss observational studies of real world data for COVID-19 medicines
7 April 2020 - In a dedicated COVID-19 workshop, organised by the EMA under the umbrella of the International Coalition of ...
Posted by Michael Wonder on 31 Mar 2020
Expanded access as a source of real‐world data: an overview of FDA and EMA approvals
22 March 2020 - The authors set out to identify, characterise, and compare all FDA and EMA approvals that included real‐world ...
Posted by Michael Wonder on 25 Mar 2020
FDA announces funding opportunity to explore the use of real-world data to generate real-world evidence in regulatory decision making
25 March 2020 - The U.S. Food and Drug Administration is announcing a funding opportunity for projects to support the ...
Posted by Michael Wonder on 24 Feb 2020
Real world evidence - from safety to a potential tool for advancing innovative ways to develop new medical therapies
24 February 2020 - Real world evidence has the potential to enhance the efficiency of drug development and provide new evidence ...
Posted by Michael Wonder on 16 Feb 2020
RWE: cost and time savings entice sponsors as pitfalls linger
14 February 2020 - The New England Journal of Medicine published an article earlier this week raising questions about the ...